Some aspects of nivolumab administration in treatment for metastatic melanoma (clinical cases)

The development of a new direction in anticancer medical therapy – the use of immune checkpoint inhibitors targeting PD-1/ PD-L1 and CTLA-4 – has significantly changed the approach to tumor treatment in the last few years. The PD1 blocker nivolumab in major registered clinical trials improved overall survival, including in metastatic melanoma, with a favorable toxicity profile. However, its efficacy in patients with brain metastases from melanoma was poorly studied, since the inclusion criteria  for  most clinical trials do not envisage recruiting such patients. The  immune-mediated toxicity of  immune checkpoint inhibitors is currently well enough studied. However, cases of cutaneous toxicity are quite rare and present certain difficulties for differential diagnosis and treatment. This article presents two cases of effective nivolumab treatment in patients with generalized BRAFwt and BRAFmut cutaneous melanoma. The  first case is of  interest due to the  presence of  brain  metastases in the patient. Nivolumab therapy helped achieving complete regression of intracranial metastases with the long-term effect. The second case, in addition to effective treatment, demonstrates a rare manifestation of skin toxicity – vitiligo on the face and upper extremities.

1. Kaprin A.D., Starinskiy V.V., Shakhzadova A.O. (eds.). The state of cancer care for the population of Russia in 2019. Moscow: Herzen Moscow Research Oncological Institute of Minzdrav of Russia; 2020. 239 p. (In Russ.) Available at: https://glavonco.ru/cancer_register/Помощь%202019.pdf.

2. Bray F., Colombet M., Mery L., Piñeros M., Znaor A., Zanetti R., Ferlay J. (eds.). Cancer incidence in Five Continents, Vol. XI (electronic version). Lyon: IARC; 2017. Available at: https://ci5.iarc.fr/ci5-xi/Default.aspx.

3. Balch C.M., Gershenwald J.E., Soong S.J., Thompson J.F., Atkins M.B., Byrd D.R. et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol. 2009;27(36):6199–6206. https://doi.org/10.1200/JCO.2009.23.4799.

4. Sloan A.E., Nock C.J., Einstein D.B. Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control. 2009;16(3): 248–255. https://doi.org/10.1177/107327480901600307.

5. Kit O.I., Frantsiyants E.M., Kotieva I.M., Kaplieva I.V., Trepitaki L.K., Bandovkina V.A. et al. Dynamics of the tissue system of plasminogen regulators in cutaneous melanoma with chronic pain in female mice. Translyatsionnaya meditsina = Translational Medicine. 2018;5(2):38–46. (In Russ.) https://doi.org/10.18705/2311-4495-2018-5-2-38-46.

6. Margolin K., Atkins B., Thompson A., Ernstoff S., Weber J., Flaherty L. et al. Temozolomide and whole brain irradiation in melanoma metastatic to the brain: a phase II trial of the Cytokine Working Group. J Cancer Res Clin Oncol. 2002;128(4):214–218. https://doi.org/10.1007/s00432-002-0323-8.

7. Long G.V., Trefzer U., Davies M.A., Kefford R.F., Ascierto P.A., Chapman P.B. et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012;13(11):1087–1095. https://doi.org/10.1016/S1470-2045(12)70431-X.

8. Dummer R., Goldinger S.M., Turtschi C.P., Eggmann N.B., Michielin O., Mitchell L. et al. Vemurafenib in patients with BRAFV600 mutation-positive melanoma with symptomatic brain metastases: Final results of an openlabel pilot study. Eur J Cancer. 2014;50(3):611–621. https://doi.org/10.1016/j.ejca.2013.11.002.

9. Ribas A., Puzanov I., Dummer R., Schadendorf D., Hamid O., Robert C. et al. Pembrolizumab versus investigator‐choice chemotherapy for ipilimumab‐ refractory melanoma (KEYNOTE‐002): A randomised, controlled, phase 2 trial. Lancet Oncol. 2015;16(8):908–918. https://doi.org/10.1016/S1470-2045(15)00083-2.

10. Reck M., Rodriguez‐Abreu D., Robingson A.G., Hui R., Csőszi T., Fülöp A. et al. Pembrolizumab versus chemotherapy for PD‐L1‐positive non‐small‐ cell lung cancer. N Engl J Med. 2016;375:1823–1833. https://doi.org/10.1056/NEJMoa1606774.

11. Motzer R.J., Escudier B., McDermott D.F., George S., Hammers H.J., Srinivas S. et al. Nivolumab versus everolimus in advanced renal‐cell carcinoma. N Engl J Med. 2015;373:1803–1813. https://doi.org/10.1056/NEJMoa1510665.

12. Peters S., Gettinger S., Johnson M.L., Jänne P.A., Garassino M.C., Christoph D. et al. Phase II trial of atezolizumab as first‐line or subsequent therapy for patients with programmed death‐ligand 1‐selected advanced non‐ small‐cell lung cancer (BIRCH). J Clin Oncol. 2017;35(24):2781–2789. https://doi.org/10.1200/JCO.2016.71.9476.

13. Alsaab H.O., Sau S., Alzhrani R., Tatiparti K., Bhise K., Kashaw S.K. et al. PD‐1 and PD‐L1 checkpoint signaling inhibition for cancer immunotherapy: Mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561. https://doi.org/10.3389/fphar.2017.00561.

14. Blank C., Brown I., Peterson A.C., Spiotto M., Iwai Y., Honjo T., Gajewski T.F. PD-L1/B7H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64(3):1140–1145. https://doi.org/10.1158/0008-5472.can-03-3259.

15. Singh B.P., Salama A.K. Updates in Therapy for Advanced Melanoma. Cancers (Basel). 2016;8(1):17. https://doi.org/10.3390/cancers8010017.

16. Parakh S., Park J.J., Mendis S., Rai R., Xu W., Lo S. et al. Efficacy of anti-PD-1 therapy in patients with melanoma brain metastases. Br J Cancer. 2017;116:1558–1563. https://doi.org/10.1038/bjc.2017.142.

17. Hellmann M.D., Rizvi N.A., Goldman J.W., Gettinger S.N., Borghaei H., Brahmer J.R. et al. Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2017;18(1):31–41. https://doi.org/10.1016/S1470-2045(16)30624-6.

18. Vokes E.E., Ready N., Felip E., Horn L., Burgio M.A., Antonia S.J. et al. Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases. Ann Oncol. 2018;29(4):959–965. https://doi.org/10.1093/annonc/mdy041.

19. Long G.V., Atkinson V., Menzies A.M., Lo S., Guminski A.D., Brown M.P. et al. A randomized phase II study of nivolumab or nivolumab combined with ipilimumab in patients (pts) with melanoma brain metastases (mets): the AntiPD1 Brain Collaboration (ABC). J Clin Oncol. 2017;35(15):9508–9508. https://doi.org/10.1200/JCO.2017.35.15_suppl.9508.

20. Collins L.K., Chapman M.S., Carter J.B., Samie F.H. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125–128. https://doi.org/10.1016/j.currproblcancer.2016.12.001.

21. Nakamura Y., Teramoto Y., Asami Y., Matsuya T., Adachi J.I., Nishikawa R., Yamamoto A. Nivolumab therapy for treatment-related vitiligo in a patient with relapsed metastatic melanoma. JAMA Dermatol. 2017;153(9):942–944. https://doi.org/10.1001/jamadermatol.2017.1679.

22. Silverberg N.B. The epidemiology of vitiligo. Current Dermatology Reports. 2015;4:36–43. https://doi.org/10.1007/s13671-014-0098-6.

23. Nordlund J.J., Kirkwood J.M., Forget B.M., Milton G., Albert D.M., Lerner A.B. Vitiligo in patients with metastatic melanoma: a good prognostic sign. J Am Acad Dermatol. 1983;9(50):689–696. https://doi.org/10.1016/S0190-9622(83)70182-9.

24. Bystryn J., Rigel D., Friedman R.J., Kopf A. Prognostic Significance of Hypopigmentation in Malignant Melanoma. Arch Dermatol. 1987;123(8): 1053–1055. https://doi.org/10.1001/archderm.1987.01660320095019.

25. Freeman-Keller M., Kim Y., Cronin H., Richards A., Gibney G., Weber J.S. Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Canc Res. 2016;22(4):886–894. https://doi.org/10.1158/1078-0432.CCR-15-1136.

26. Hua C., Boussemart L., Mateus C., Routier E., Boutros C., Cazenave H. et al. Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016;152(1):45–51. https://doi.org/10.1001/jamadermatol.2015.2707.

27. Schallreuter K.U., Levenig C., Berger J. Vitiligo and cutaneous melanoma. A case study. Dermatologica. 1991;183:239–245. https://doi.org/10.1159/000247693.

28. Bertolotti A., Boniface K., Vergier B., Mossalayi D., Taieb A., Ezzedine K. et al. Type I interferon signature in the initiation of the immune response in vitiligo. Pigment Cell Melanoma Res. 2014;27(3):398–407. https://doi.org/10.1111/pcmr.12219.